ZMapp Effective Against Ebola in Nonhuman Primates

A combination of three humanized antibodies produced in tobacco plants protected rhesus macaques when initiated up to 5 days after lethal challenge with EBOV.

The use of an investigational combination monoclonal antibody preparation, ZMapp, for the treatment of two American healthcare workers who contracted Ebola virus (EBOV) disease in Liberia brought international attention to this therapeutic approach. A team of researchers, including industry members, has now published data on the efficacy of ZMapp in experimentally infected rhesus macaques.

Previous work by this research group had shown that a combination of three murine monoclonal antibodies could effectively treat rhesus macaques challenged with EBOV 48 hours earlier (NEJM JW Infect Dis Jul 11 2012). The researchers subsequently sought to improve the monoclonal antibody cocktail. To extend the half-life of the antibodies in humans, they chi…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

ZMapp Effective Against Ebola in Nonhuman Primates

Topics

Reviewing Author